LFB spinout debuts with CD20 mAb

TG Therapeutics Inc. (OTCBB:TGTX) made its public debut on Friday with an exclusive, worldwide license from former parent company LFB S.A. (Les Ulis, France) to develop and commercialize ublituximab ( LFB-R603). The chimeric recombinant mAb against CD20 has completed a Phase I/II trial in patients with relapsed chronic lymphocytic leukemia (CLL). TG Therapeutics plans to develop ublituximab for B-cell proliferative disorders. ...